Perampanel + Placebo
Phase 3Completed 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Partial-onset Seizures
Conditions
Partial-onset Seizures
Trial Timeline
May 15, 2012 → May 28, 2020
NCT ID
NCT01618695About Perampanel + Placebo
Perampanel + Placebo is a phase 3 stage product being developed by Eisai for Partial-onset Seizures. The current trial status is completed. This product is registered under clinical trial identifier NCT01618695. Target conditions include Partial-onset Seizures.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (4)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02220972 | Approved | Withdrawn |
| NCT01618695 | Phase 3 | Completed |
| NCT01161524 | Phase 2 | Completed |
| NCT00566462 | Phase 2 | Terminated |
Competing Products
2 competing products in Partial-onset Seizures
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Perampanel | Eisai | Phase 3 | 77 |
| Lacosamide | UCB | Phase 3 | 74 |